|
(Exact name of registrant as specified in its charter)
|
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
(Former name or former address, if changed since last report.)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
|
|
|
|
-
|
|
Item 1.02 |
Termination of a Material Definitive Agreement
|
August 17, 2021
|
ADMA Biologics, Inc.
|
||
|
|
||
|
By:
|
/s/ Brian Lenz
|
|
|
|
Name:
|
Brian Lenz
|
|
|
Title:
|
Executive Vice President and Chief Financial Officer
|
-8?20$3;
M8T.P6BP^0"X99K>]9!:G
/"]_FPJ5)N-B))AU88H#/M<\QHQ[BV( H^JM,]]
M1VVA:Y39.B;38HSY7. J&<[5-4A4:;WN)TI#7F^B)<@6T/+F0Q7$.)AUB,_U
M=A#5^*#6N53UC]59].>%U;KT-GA=M93J=%^6MG^[2"%MMN_Q,-XTWR KMSR G4A?#UYI;KM E_@DWU0$R-&S)"%-RTVVUUK@O3PY
M'Z>>GSI6=R#8=[DI2T?@'H/1QP6'%]\13X3Q+>(2"Q'CQ&G^1O+,8Q*DH+$S
M$7&9P0QH'H[#C$8B'J?AA*2PG$[]B6Q9-(@]@).6\1(LJ&T[R&U-0J-)6>:#
MB,>WV Y=]@!#$>F4$ELSFZ2+-Z97(@$;=T@ SF7 ^I$,6N)/DF(I& V].+
M +QQ'N,Y;&FM'"/;G= ]]KX%U,/Y!]1S88A//P_4$L! A0#% @ N(414^O).@C0 P .Q$
M !$ ( ! &%D;6$M,C R,3 X,38MZBGQLU-;F [P]GKB$.8VFKR(F-W2%$\*P7>*.1.#P M
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M8!I\;7%_6:Q]9EC,K&4L3 1=$I-[_3/@]E